课题基金 / 基金详情

ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA

ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
抗 C20 IDEC C2B8（利妥昔单抗）治疗艾滋病相关非霍奇金淋巴瘤
批准号：
6302997
负责人：
MANSOOR N SALEH
金额：
$2.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6302997
关键词：
AIDS related neoplasm /cancer AIDS therapy antineoplastics clinical research drug screening /evaluation human subject human therapy evaluation neoplasm /cancer chemotherapy nonHodgkin's lymphoma virus load

项目摘要

项目成果

MANSOOR N SALEH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To date 2 patients with signs of associated aggressive non-Hodgkin's lymphoma have been treated on study. Patient #1 completed 8 cycles Patient #2 died of progressive disease following the first treatment (3 cycles) Patient #1 achieved a PR. No increase in infectious complications or opportunistic infections were observed in this study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
海外基金